Table 1.
Baseline demographic and clinical characteristics and outcomes of the patients given DMB therapy and control patients
| DMB (n = 17) | Control (n = 26) | P-value | |
|---|---|---|---|
| Baseline characteristics | |||
| Age, y, mean (SD) | 58.4 (7) | 64.1 (7.9) | 0.021 |
| Male, n (%) | 11 (64.7) | 15 (57.7) | 0.755 |
| Female, n (%) | 6 (35.3) | 11 (42.3) | 0.755 |
| Comorbidities, n (%) | 8 (47) | 20 (76.9) | 0.057 |
| DM | 0 (0) | 6 (23.1) | 0.066 |
| Hypertension | 6 (35.3) | 18 (69.2) | 0.058 |
| Hyperlipidemia | 5 (29.4) | 15 (57.7) | 0.118 |
| CVD | 1 (6) | 6 (23) | 0.376 |
| Asthma/COPD | 2 (11.7) | 2 (7.7) | 1.000 |
| Stroke | 0 (0) | 2 (7.7) | 0.511 |
| Clinical features | |||
| Normal CXR on admission, n (%) | 7 (41.2) | 7 (26.9) | 0.507 |
| Time from onset of symptoms to admission, d, median (IQR) | 7 (1–9) | 5 (3–8) | 0.455 |
| Time from onset of symptom to initiation of therapy, d, median (IQR) | 7 (4–10) | ||
| Time from admission to initiation of therapy, d, median (IQR) | 1 (0–1) | ||
| Duration of therapy, d, median (IQR) | 5 (4–7) | ||
| Treatment with Kaletra/remdesivir/hydroxychloroquine, n (respective numbers), % | 3 (1/2/0), 17.6 | 16 (8/7/1), 61.5 | |
| Outcome | |||
| - Requiring oxygen therapy (including ICU support), n (%) | 3 (17.6) | 16 (61.5) | 0.006 |
| - Requiring oxygen therapy (but no ICU support), n (%) | 2 (11.8) | 8 (30.8) | |
| - Requiring ICU support, n (%) | 1 (5.9) | 8 (30.8) | |
| - Mortality, n (%) | 0 (0) | 0 (0) | |
CVD, cardiovascular disease; CXR, chest x-ray; DM, diabetes mellitus; DMB, vitamin D, magnesium, vitamin B12; ICU, intensive care unit; IQR, interquartile range.
P-values < 0.05 are highlighted in bold.